Heterogeneity of Treatment Effect of Aspirin and Clinically Significant Bleeding in Older Adults
Authors:
- Giorgos TzimasGTGiorgos Tzimas
- Roselyne B. TchouaRTRoselyne B. Tchoua
- Joseph C. VanghelofJVJoseph C. Vanghelof
- Rory WolfeRWRory Wolfe
- Geoffrey CloudGCGeoffrey Cloud
- Suzanne E. MahadySMSuzanne E. Mahady
- Lianlian DuLDLianlian Du
- Michael E. ErnstMEMichael E. Ernst
- Erica M. WoodEWErica M. Wood
- Daniela S. RaicuDRDaniela S. Raicu
- Shara KetSKShara Ket
- Raj C. ShahRSRaj C. Shah
Preprint
Abstract
Aim: The global population of older adults is growing, and older age is linked to higher bleeding risk. Although guidelines discourage aspirin for primary prevention in healthy older adults due to bleeding harms outweighing benefits, many continue taking it without a clear indication. It remains unclear whether all older adults face uniform aspirin-related bleeding risk or if certain subgroups are more vulnerable. Methods: We analyzed data from 19,114 ASPREE trial participants to develop machine learning models using 116 baseline variables. Random forest (RF) and random survival forest (RSF) models predicted 5-year bleeding risk, and participants were stratified into low, intermediate, and high-risk groups based on the 20th and 80th percentiles of predicted risk. We assessed heterogeneity of treatment effect (HTE) by testing treatment-by-risk group interactions on the relative scale using Fine-Gray models, and on the absolute scale using observed 5-year cumulative incidence rates. Results: Over a median follow-up of 4.7 years, 626 major bleeding events occurred. The RF model had moderate discrimination (AUC = 0.65, 95% CI: 0.63-0.67) and good calibration (Brier = 0.032, 95% CI: 0.029-0.034). Statistically significant HTE was observed on the relative scale, with the greatest relative increase in bleeding risk seen in the low-risk group (subdistribution hazard ratio = 2.26, 95% CI: 1.27–4.01). On the absolute scale, low-risk participants experienced higher bleeding with aspirin (absolute risk difference (ARD) = 1.17%, 95% CI: 0.37–1.95), but heterogeneity in ARDs was not statistically significant (Cochran’s Q p > 0.45). Similar findings were observed when using the RSF model. Conclusion: Participants at lowest baseline bleeding risk experienced the greatest relative increase in bleeding risk with aspirin therapy. We found statistically significant heterogeneity in treatment effects on the relative but not absolute scale. These findings support an individualized, risk-based approach to aspirin therapy decision-making in older adults.Keywords
Funding Information
- National Institutes of Health (U01AG029824)
- National Institutes of Health (U19AG062682)
- National Science Foundation (1950894)
This publication has 19 references indexed in Scilit:
- Aspirin Use to Prevent Cardiovascular DiseaseJAMA, 2022
- Heterogeneity of Treatment EffectJAMA, 2021
- Aspirin Use and Misuse for the Primary Prevention of Cardiovascular DiseasesAmerican Journal of Preventive Medicine, 2021
- Effect of Aspirin on Disability-free Survival in the Healthy ElderlyNew England Journal of Medicine, 2018
- Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trialContemporary Clinical Trials Communications, 2018
- Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort studyThe Lancet, 2017
- Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trialContemporary Clinical Trials, 2013
- Association of Aspirin Use With Major Bleeding in Patients With and Without DiabetesJAMA, 2012
- Random ForestsMachine Learning, 2001
- Assessment and comparison of prognostic classification schemes for survival dataStatistics in Medicine, 1999